ProQR Therapeutics N.V. logo
ProQR Therapeutics N.V. PRQR
$ 1.09 -5.22%
report update icon

Quarterly report 2022-Q3
added 10-28-2026

ProQR Therapeutics N.V. Net Income | PRQR

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income ProQR Therapeutics N.V.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-42.2 M -27.8 M -27.7 M -64.2 M -61.7 M -46.6 M -56.5 M -36.9 M -43.6 M -39.1 M -20.8 M -12.1 M -3.25 M - -

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
-3.25 M -64.2 M -37.1 M

Quarterly Net Income ProQR Therapeutics N.V.

2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-42.2 M -11 M -12.2 M -10.1 M -27.8 M -8.11 M -2.69 M -7.66 M -27.7 M -5.42 M -7.98 M -8.86 M - -23.3 M -13.5 M -14.4 M -18.2 M -15.1 M -15.8 M -12.6 M -13.2 M -13.2 M -4.12 M -16.1 M -18.6 M -12.2 M -11.7 M -14.2 M - -5.99 M -7.4 M - - - -11.4 M - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Indicator range from quarterly reporting

Maximum Minimum Average
-2.69 M -42.2 M -13.8 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
-38.6 M $ 36.28 1.88 % $ 2.05 B usaUSA
TG Therapeutics TG Therapeutics
TGTX
447 M $ 66.13 5.45 % $ 9.54 B usaUSA
Aphria Inc. Aphria Inc.
APHA
-84.6 M - -0.45 % $ 4.87 B canadaCanada
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
-4.32 M - -0.90 % $ 104 M usaUSA
Chiasma, Inc. Chiasma, Inc.
CHMA
-74.8 M - -6.00 % $ 238 M usaUSA
Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals, Inc.
ADMS
-57.4 M - - $ 376 M usaUSA
Cellect Biotechnology Ltd. Cellect Biotechnology Ltd.
APOP
16.8 M - 0.38 % $ 12.9 M israelIsrael
AzurRx BioPharma, Inc. AzurRx BioPharma, Inc.
AZRX
-32.7 T - 2.07 % $ 34.4 M usaUSA
Cerecor Inc. Cerecor Inc.
CERC
-63.5 M - -1.68 % $ 283 M usaUSA
Constellation Pharmaceuticals, Inc. Constellation Pharmaceuticals, Inc.
CNST
-126 M - - $ 1.63 B usaUSA
Auris Medical Holding Ltd. Auris Medical Holding Ltd.
EARS
-8.2 M - -1.77 % $ 39.2 M bermudaBermuda
Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc.
DRNA
-113 M - 0.34 % $ 2.98 B usaUSA
ERYTECH Pharma S.A. ERYTECH Pharma S.A.
ERYP
-228 K - 1.3 % $ 27.7 M franceFrance
GW Pharmaceuticals plc GW Pharmaceuticals plc
GWPH
-58.1 M - - $ 6.81 B britainBritain
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
-109 M - - $ 1.7 B usaUSA
Liminal BioSciences Liminal BioSciences
LMNL
622 K - - $ 256 M canadaCanada
argenx SE argenx SE
ARGX
1.29 B $ 940.88 -0.7 % $ 57.7 B niderlandNiderland
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
-124 M $ 2.86 -4.25 % $ 24.3 M usaUSA
Neos Therapeutics, Inc. Neos Therapeutics, Inc.
NEOS
-16.9 M - -2.54 % $ 57.2 M usaUSA
Xenetic Biosciences Xenetic Biosciences
XBIO
-2.68 M $ 1.52 -5.59 % $ 2.59 M usaUSA
Odonate Therapeutics, Inc. Odonate Therapeutics, Inc.
ODT
-126 M - -3.18 % $ 58.5 M usaUSA
Orphazyme A/S Orphazyme A/S
ORPH
-633 M - -2.25 % $ 31.3 M danmarkDanmark
Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc
OSMT
-79.6 M - -10.74 % $ 89.9 M usaUSA
Pandion Therapeutics, Inc. Pandion Therapeutics, Inc.
PAND
-38.1 M - - $ 1.77 B usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
-346 M $ 37.93 -2.19 % $ 3.01 B canadaCanada
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
554 K $ 16.95 0.92 % $ 2.72 B usaUSA
22nd Century Group 22nd Century Group
XXII
-5.05 M $ 0.38 -14.05 % $ 69.9 K usaUSA
Translate Bio, Inc. Translate Bio, Inc.
TBIO
-53.8 M - - $ 2.81 B usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
-59.3 M - - $ 1.94 B canadaCanada
Urovant Sciences Ltd. Urovant Sciences Ltd.
UROV
-147 M - - $ 532 M britainBritain
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
-125 M - - $ 10.9 B usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
-1.02 B - 0.52 % $ 821 M danmarkDanmark
Zogenix, Inc. Zogenix, Inc.
ZGNX
-209 M - -4.97 % $ 664 M usaUSA
Yunhong International Yunhong International
ZGYH
-797 K - 0.10 % $ 92.2 M chinaChina
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.
ZIOP
-80 M - -7.58 % $ 264 M usaUSA
Taysha Gene Therapies Taysha Gene Therapies
TSHA
-109 M $ 3.99 -0.25 % $ 1.28 B usaUSA
Zentalis Pharmaceuticals Zentalis Pharmaceuticals
ZNTL
-137 M $ 1.38 -7.38 % $ 99.2 M usaUSA
Zoetis Zoetis
ZTS
2.67 B $ 85.52 2.44 % $ 37.9 B usaUSA
Vanda Pharmaceuticals Vanda Pharmaceuticals
VNDA
-220 M $ 3.76 -1.44 % $ 222 M usaUSA
Vericel Corporation Vericel Corporation
VCEL
16.5 M $ 58.63 1.29 % $ 2.95 B usaUSA
Veracyte Veracyte
VCYT
66.4 M $ 25.54 5.41 % $ 2.01 B usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
-69.7 M $ 0.2 5.69 % $ 7.61 M usaUSA
Viking Therapeutics Viking Therapeutics
VKTX
-360 M $ 26.19 -2.59 % $ 2.95 B usaUSA
Voyager Therapeutics Voyager Therapeutics
VYGR
-120 M $ 1.68 10.2 % $ 98.6 M usaUSA
Zai Lab Limited Zai Lab Limited
ZLAB
-176 M $ 22.11 -6.03 % $ 24.2 B chinaChina
Verrica Pharmaceuticals Verrica Pharmaceuticals
VRCA
-17.9 M $ 2.9 -7.64 % $ 30.9 M usaUSA
Wave Life Sciences Ltd. Wave Life Sciences Ltd.
WVE
-204 M $ 2.77 -2.64 % $ 467 M singaporeSingapore
Zymeworks Zymeworks
ZYME
-212 M $ 26.04 0.77 % $ 1.34 B canadaCanada
XBiotech XBiotech
XBIT
-45.5 M $ 1.76 -1.12 % $ 53.7 M usaUSA
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd.
XTLB
-1.03 M $ 1.54 -4.94 % $ 1.04 B israelIsrael